IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates

Core Viewpoint - IGC Pharma, Inc. reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.03, marking a 33.33% earnings surprise [1][2] Financial Performance - The company posted revenues of $0.26 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 28.50%, compared to $0.2 million in the same quarter last year [2] - Over the last four quarters, IGC Pharma has surpassed consensus EPS estimates two times [2] Stock Performance - IGC Pharma shares have declined approximately 9% since the beginning of the year, while the S&P 500 has gained 4% [3] - The current Zacks Rank for IGC Pharma is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $0.3 million, and for the current fiscal year, it is -$0.11 on revenues of $1.18 million [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which could influence future stock movements [6][7] Industry Context - The Medical - Drugs industry, to which IGC Pharma belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, United Therapeutics, is expected to report quarterly earnings of $6.23 per share, reflecting a year-over-year increase of 42.9% [9]